Retrospective cross-sectional study evaluates the F/B ratio's impact on abdominal obesity and insulin resistance in Korean adults, indicating potential metabolic risks.
The gut microbiota has been increasingly implicated in the pathogenesis of obesity and insulin resistance. The Firmicutes/Bacteroidetes (F/B) ratio may serve as a marker of metabolic health; nonetheless, evidence for its association with abdominal obesity and insulin resistance in Asian populations remains scarce. This retrospective cross-sectional study included 186 Korean adults undergoing health check-ups. Gut microbiota composition was assessed by 16S rRNA gene sequencing, and the phylum-level F/B ratio was calculated. Abdominal obesity was defined using waist circumference criteria for Asian populations, and insulin resistance was evaluated using the metabolic score for insulin resistance (METS-IR). Participants were categorized into F/B ratio quartiles. Associations between the F/B ratio, abdominal obesity, and insulin resistance were examined using linear and logistic regression analyses with adjustment for potential confounders. Higher F/B ratios were inversely associated with waist circumference and METS-IR. Abdominal obesity prevalence decreased progressively across increasing F/B ratio quartiles. In multivariable linear regression analyses, the F/B ratio remained independently associated with lower METS-IR (β = - 0.911, p = 0.040). In fully adjusted logistic regression models, participants in the highest F/B ratio quartile had significantly lower odds of abdominal obesity than did those in the lowest quartile (OR = 0.17, 95% CI 0.05-0.59). In Korean adults, the gut microbial F/B ratio was inversely associated with abdominal obesity and insulin resistance, as assessed by METS-IR, a composite index reflecting adiposity-related metabolic dysfunction. These findings suggest that gut microbiota composition may be metabolically relevant to visceral adiposity-related metabolic dysfunction and that the F/B ratio could serve as a complementary indicator for metabolic risk stratification.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: